# DeepMirror

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deepmirror

- Industry: Software
- Headquarters: London, UK
- Website: www.deepmirror.ai
- Total disclosed funding: $1.6M
- Latest round: Seed (Aug 6, 2024)
- Investors on record: 4

## About

Founded in 2019 and based in London, UK, DeepMirror Ltd operates as a healthcare technology company that specializes in the integration of artificial intelligence with traditional medicinal chemistry to enhance the drug discovery process. The company was spun out from the University of Cambridge and was founded by Max Jakobs (CEO), Andrea Dimitracopoulos, and Ryan Greenhalgh. In December 2024, DeepMirror Ltd raised USD 2.4 million in seed funding led by Twinpath Ventures, Innovate UK Investor Partnership, Saras Capital, and stealth.vc.

DeepMirror offers the DeepMirror App, which integrates artificial intelligence with traditional medicinal chemistry to streamline the drug discovery process. This platform allows medicinal chemists to predict and classify the biological activity of various compounds, providing chemical suggestions for testing. Tailored for pharmaceutical and biotechnology sectors, the application supports medicinal chemists of all expertise levels and is marketed in regions with pharmaceutical industries, including North America, Europe, and parts of Asia.

The company plans to utilize the December 2024 funding raised to accelerate the enhancement of its AI-powered platform.

## Funding rounds

- Seed, Aug 6, 2024, $1.6M — Innovate UK, Saras Capital, Twin Path Ventures, Stealth VC

## Investors

- Innovate UK — Seed
- Saras Capital (https://capitalatlas.ai/funds/saras-capital) — Seed
- Twin Path Ventures (https://capitalatlas.ai/funds/twin-path-ventures) — Seed
- Stealth VC — Seed